{"Clinical Trial ID": "NCT01129622", "Intervention": ["INTERVENTION 1:", "Letrozole, Breast improvement, Safety", "12.5 mg/day letrozole is given for three consecutive days just before the second MRI."], "Eligibility": ["Incorporation criteria:", "Women can participate if they are 40 years of age or older and have been menopausal (without menstrual bleeding in the last 12 months)", "- Exclusion criteria:", "History of bilateral mastectomy, osteoporosis or renal failure."], "Results": ["Performance measures:", "Number of women with reduced breast parenchyma", "A region of interest was selected for all images. The intensity of the improvement signal was recorded and the relative improvement (percentage of the increase in signal intensity) was calculated as (Sic - SI)/SI \u00d7 100, where SI and Sic are the prestress and poststress signal intensities respectively. The relative improvement was compared to the basic MRI study and the MRI study after one month for all participants.", "Timeline: One month post-letrozole MRI study compared to the initial MRI study, both with improved gadolinium", "Results 1:", "Title of the arm/group : Letrozole, Breast improvement, Safety", "A single arm of healthy menopausal women to have two mammary MRIs (base and post-treatment) The 12.5 mg/day letrozole is given for three consecutive days just before the second MRI.", "Total number of participants analysed: 14", "Type of measurement: Number", "Unit of measure: Number of participants 7"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/14 (0.00 per cent)"]}